Samuji Mat, O'Sullivan R, Shireen R
Department of Radiation Oncology, Cork University Hospital, Wilton, Cork.
Ir Med J. 2013 Sep;106(8):246.
Tamoxifen has been shown to significantly reduce the risk of tumour recurrence in women with receptor positive breast cancer and has been used for chemoprevention in women with both non-invasive cancer and those with a high risk of developing breast cancer. An established and accepted risk with this treatment is the increased incidence of adenocarcinoma of the endometrium. Less well recognised is uterine sarcoma, a rare and aggressive tumour accounting for under five percent of uterine malignancies, with five year survival rates in the order of 50%.
